文献速递神经肿瘤神经重症

立体定向脑活检诊断率与手术安全性的预测因素

Predictors of diagnostic yield and surgical safety in stereotactic brain biopsy.
PubMed 文献 · J Neurooncol · 2026-04-17

该研究回顾性分析了2014至2025年间在三级学术中心接受立体定向脑活检的725例成年患者,总体诊断率为95.0%,并发症率为4.69%。低诊断率病理(如低级别胶质瘤、炎性/感染性病变)是非诊断结果的唯一独立预测因素(OR 4.22),深部位置是术后出血的唯一独立预测因素(OR 3.93)。机器人、无框架和框架导航平台间诊断率与安全性无统计学差异。

要点

  • 低诊断率病理(如低级别胶质瘤、炎性/感染性病变)是非诊断结果的唯一独立预测因素(OR 4.22)。
  • 深部位置是术后出血的唯一独立预测因素(OR 3.93)。
  • 机器人、无框架和框架导航平台间诊断率与安全性无统计学差异(p > 0.80)。

核心结论

  • 立体定向脑活检在各类导航平台上均表现出高诊断准确性和安全性。
  • 病变生物学是决定非诊断采样的主要因素,深部位置是出血的主要风险因素。

研究设计与样本

  • 回顾性队列研究,纳入2014至2025年间在三级学术中心接受立体定向脑活检的725例成年患者(≥18岁)。
  • 采用1:4最近邻匹配病例对照设计评估非诊断结果(n=184)和术后出血(n=95)的预测因素,控制年龄和技术变迁。
  • 使用多变量逻辑回归计算比值比(OR)和95%置信区间(CI)。

主要发现

  • 总体诊断率为95.0%,总体并发症率为4.69%。
  • 低诊断率病理是非诊断结果的唯一独立预测因素(OR 4.22, 95% CI 1.77–10.06, p = 0.001)。
  • 深部位置是术后出血的唯一独立预测因素(OR 3.93, 95% CI 1.24–12.46, p = 0.019)。
  • 机器人、无框架和框架导航平台间诊断率或安全性无统计学差异(p > 0.80)。
  • 中位住院时间为1天(均值3.92 ± 5.23天),研究期间显著下降(p = 0.023);诊断与非诊断组住院时间相同。

临床怎么用

  • 对于低诊断率病理(如低级别胶质瘤、炎性/感染性病变),应预期可能的非诊断结果并规划后续策略。
  • 对于深部病变,应加强术后出血监测与防范。
  • 导航平台选择不影响诊断率或安全性,可根据可用性决定。
  • 研究结果支持在现代神经肿瘤学中实施标准化早期出院路径。

局限性

  • 回顾性单中心研究,结果外推需谨慎。
  • 未报告其他潜在混杂因素的控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic brain biopsy (SBB) is a fundamental diagnostic procedure for intracranial lesions that are radiographically indeterminate or surgically inaccessible. While advances in navigation and perioperative care have enhanced safety, high-granularity data identifying independent predictors of diagnostic failure and complications in large longitudinal cohorts remain limited. METHODS: We retrospectively reviewed 725 adult patients (≥18 years) who underwent SBB at a tertiary academic center between 2014 and 2025. Primary outcomes included diagnostic yield and procedure-related complications, specifically postoperative hemorrhage. A 1:4 nearest-neighbor matched case-control design was used to assess predictors of non-diagnostic yield (n = 184) and postoperative hemorrhage (n = 95), controlling for age and temporal technological changes. Multivariate logistic regression was utilized to calculate odds ratios (OR) and 95% confidence intervals (CI). RESULTS: The overall diagnostic yield was 95.0% and the overall complication rate was 4.69%. Multivariate analysis revealed that low-yield pathology (e.g., low-grade glioma, inflammatory, or infectious lesions) was the sole independent predictor of a non-diagnostic result (OR 4.22, 95% CI 1.77–10.06, p = 0.001). Regarding surgical safety, deep-seated location was the only independent predictor of postoperative hemorrhage (OR 3.93, 95% CI 1.24–12.46, p = 0.019). Notably, no statistical differences in yield or safety were observed between robotic, frameless, and frame-based navigation platforms (p > 0.80). Median LOS was 1 day (mean 3.92 ± 5.23 days) and significantly declined over the study period (p = 0.023). Comparative analysis showed that LOS was identical between diagnostic and non-diagnostic groups. CONCLUSIONS: Over a decade of institutional experience, SBB demonstrated high diagnostic accuracy and safety across all navigation platforms. These findings identify lesion biology as the primary driver of non-diagnostic sampling and deep-seated location as the chief risk factor for hemorrhage. The comparable hospital resource utilization regardless of diagnostic outcome, combined with a declining LOS, supports the feasibility of standardized early-discharge pathways in modern neuro-oncology. CLINICAL TRIAL NUMBER: Not applicable.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ghoche MT, Gecici NN, Miki K, et al. Predictors of diagnostic yield and surgical safety in stereotactic brain biopsy. J Neurooncol. 2026. PMID: 41995978. doi:10.1007/s11060-026-05573-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。